| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
|
Blood
|
2008
|
3.52
|
|
2
|
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
|
Biol Blood Marrow Transplant
|
2011
|
2.63
|
|
3
|
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
2.45
|
|
4
|
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.
|
J Clin Oncol
|
2003
|
1.70
|
|
5
|
CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans.
|
Blood
|
2003
|
1.65
|
|
6
|
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.
|
Exp Hematol
|
2004
|
1.50
|
|
7
|
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
|
J Clin Oncol
|
2005
|
1.42
|
|
8
|
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
1.33
|
|
9
|
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.
|
J Clin Oncol
|
2004
|
1.28
|
|
10
|
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
|
Blood
|
2013
|
1.27
|
|
11
|
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
|
Biol Blood Marrow Transplant
|
2013
|
1.25
|
|
12
|
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type.
|
Haematologica
|
2010
|
1.25
|
|
13
|
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.
|
Blood
|
2012
|
1.22
|
|
14
|
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
|
Adv Hematol
|
2011
|
1.12
|
|
15
|
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.
|
Am J Hematol
|
2009
|
1.07
|
|
16
|
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.
|
Br J Haematol
|
2008
|
1.03
|
|
17
|
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Haematologica
|
2009
|
1.02
|
|
18
|
Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score.
|
Cancer
|
2003
|
1.00
|
|
19
|
Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.
|
Biol Blood Marrow Transplant
|
2009
|
1.00
|
|
20
|
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
|
Leuk Lymphoma
|
2012
|
0.96
|
|
21
|
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
|
Biol Blood Marrow Transplant
|
2008
|
0.93
|
|
22
|
Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.
|
Biol Blood Marrow Transplant
|
2008
|
0.93
|
|
23
|
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.
|
Br J Haematol
|
2007
|
0.93
|
|
24
|
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
|
Biol Blood Marrow Transplant
|
2007
|
0.93
|
|
25
|
Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.
|
Transfusion
|
2006
|
0.90
|
|
26
|
Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction.
|
Biol Blood Marrow Transplant
|
2009
|
0.87
|
|
27
|
Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.86
|
|
28
|
Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.
|
Biol Blood Marrow Transplant
|
2011
|
0.84
|
|
29
|
Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci.
|
Biol Blood Marrow Transplant
|
2010
|
0.84
|
|
30
|
Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
0.83
|
|
31
|
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
|
Biol Blood Marrow Transplant
|
2007
|
0.82
|
|
32
|
Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma.
|
Leuk Lymphoma
|
2006
|
0.82
|
|
33
|
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2006
|
0.80
|
|
34
|
Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation.
|
Haematologica
|
2005
|
0.79
|
|
35
|
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
|
Leuk Lymphoma
|
2011
|
0.78
|
|
36
|
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.76
|
|
37
|
Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
|
Cancer
|
2013
|
0.75
|
|
38
|
Histologic Grade 1 is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.
|
Am J Surg Pathol
|
2017
|
0.75
|
|
39
|
Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers.
|
Transfusion
|
2013
|
0.75
|